Introduction {#s1}
============

Prostate cancer is the second most common cancer in males according to the International Agency for Research on Cancer ([@B1]). The outcomes of radiotherapy are equal or better than those of surgery ([@B2]). One type of radiotherapy, carbon-ion radiotherapy (CIRT), reportedly reduces the risk of acute and late toxicities with outcomes that are equal or better than those of conformal radiotherapy and intensity-modulated radiation therapy ([@B3]--[@B7]).

Carbon-ion beams provide sharper dose distributions than photon beams because they benefit from the Blagg peak and a sharp lateral penumbra ([@B8], [@B9]). However, carbon-ion beams are sensitive to changes in the target position or water-equivalent path length (WEL) to the target, which may result in changes in dose distributions ([@B10]--[@B14]). The reproducibility of dose distributions for inter-fractional anatomical changes is very important to ensure safe treatment of patients; however, few reports have focused on this topic in the context CIRT for prostate cancer.

In our previous study, we evaluated the influence of the beam field angle during setup the range uncertainty on the rectal and target doses in CIRT for prostate cancer ([@B15]). Our results showed that the prostate and rectal dose deviations did not vary significantly with the field angle. However, while the setup uncertainty was considered in this study, inter-fractional anatomical changes in the prostate, bladder, and/or rectum were not. To improve the safety of CIRT, it is necessary to evaluate the influence of such anatomical changes on the dose distribution. Additionally, whether a vertical or horizontal field is more robust against inter-fractional changes remains unclear. Further, because a vertical field must be used instead of a horizontal field in certain cases, such as when the patient has a metal hip implant, it is important to evaluate the robustness of a vertical field against inter-fractional changes. Hence, in this study, we evaluated the robustness of horizontal and vertical fields against inter-fractional anatomical changes using daily computed tomography (CT) images acquired in a treatment room.

Materials and Methods {#s2}
=====================

Patient
-------

This prospective study included 10 consecutive patients with prostate cancer who had agreed to participate in this study and had been treated with 12 fractions of passive-irradiation CIRT at Gunma University Heavy Ion Medical Center from June 2017 to March 2018. The patients\' characteristics are detailed in [Table 1](#T1){ref-type="table"}. This study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board at Gunma University Hospital (1564). The study was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR trial number: 000029495). All patients provided written informed consent to participate in this study and their data were anonymized.

###### 

Patient characteristics.

  **Patient Number**   **Age**   **Prostate Volume (ml)**   **Rectal Volume (ml)**   **Bladder Volume (ml)**
  -------------------- --------- -------------------------- ------------------------ -------------------------
  P1                   67        17.2                       48.5                     322.5
  P2                   72        18.7                       70.5                     192.8
  P3                   59        22.0                       68.9                     198.5
  P4                   76        17.4                       38.7                     214.2
  P5                   73        23.4                       44.6                     139.1
  P6                   76        20.6                       48.0                     146.3
  P7                   66        15.0                       31.7                     155.4
  P8                   70        18.5                       39.8                     113.3
  P9                   60        32.8                       35.5                     89.7
  P10                  78        19.2                       61.1                     105.2
  Median               71        18.95                      46.3                     150.85

*The prostate, rectal, and bladder volumes were measured from the treatment planning CT*.

CT Image Acquisition and Actual Treatment
-----------------------------------------

Twelve CT data sets were acquired on each day of treatment to investigate the effects of tumor movement and inter-fractional changes on the dose decided in the treatment planning stage. All patients were immobilized in the supine position by a shell fitter (Kuraray, Tokyo, Japan) to depress the abdomen and prevent body movement. A MoldCare cushion (Alcare, Tokyo, Japan) was used to provide trunk support while the patient was irradiated and CT images were acquired. CT images for treatment planning (PlanCT) were acquired on a scanner (Aquilion LB®, Self-Propelled; Canon Medical Systems, Otawara, Tochigi, Japan) in a simulation room.

Each patient retained his urine for 20 min before entering the irradiation room. The patient was positioned with the aid of orthogonal X-ray imaging ([@B16], [@B17]). If gas or feces was observed inside or close to the target on the X-ray images, a degassing or enema procedure was performed. This radiotherapy irradiation procedure was performed on each of the 12 separate days. After the radiotherapy, one set of CT images was acquired using a treatment-room CT (TRCT) system of the same type as in the simulation room ([@B18]). TRCT image sets were obtained from each patient in the same position as used for irradiation and with the same tube voltage, tube current, field of view, and slice thickness settings used for the PlanCT.

Treatment Planning
------------------

In this study, we used a CIRT system ([@B19]) with a heavy ion irradiation device (Mitsubishi Electric, Tokyo, Japan) with passive irradiation ([@B20]) and a treatment planning system (TPS) (XiO-N, Mitsubishi Electric). The passive irradiation field was generated using a scatterer and wobbling, and the field was collimated to the outside of the planning target volume (PTV) using a multi-leaf collimator. A pencil-beam algorithm was used to calculate the dose distributions ([@B21], [@B22]). The relative biological effectiveness (RBE) was included in the absorbed dose using a spread-out Bragg peak concept ([@B23]), and the clinical dose was defined as Gy (RBE). The PTV1 for the prostate cancer treatment for each patient was determined after adding 8-mm anterior and lateral margins, 6-mm cranial and caudal margins, and a 5-mm posterior margin to the prostate as well as 3-mm lateral margins, 5-mm cranial and caudal margins, and a 5-mm posterior margin to the proximal seminal vesicle. The PTV2 was created by subtracting 6 mm from the circumscribed position of the PTV1 in the cranial and caudal directions and subtracting the circumscribed region of the rectum in the posterior direction of PTV1 from the PTV1. The CIRT plan was generated such that the percentages of PTV1 and PTV2 receiving \>95% of the prescribed dose (V95) were \>95%. Irradiation was applied with fields from the left and right sides. Two of the fields were applied in four fractions, and the other two were applied in two fractions, which results in an initial field of 8 fractions to PTV1 and a boost field of 4 fractions to PTV2; thus, there was a total of 12 fractions. Each fraction was 4.3 Gy (RBE), and the total dose was therefore 4.3 × 12 = 51.6 Gy (RBE).

Data Analysis
-------------

The inter-fractional prostate displacements were measured from bone-matching positions to prostate-matching positions between the PlanCT and subsequent TRCT images for each patient (*n* = 118; 2 CT sets were not acquired because of a CT system failure) using commercial software (MIM Maestro® MIM Software, Cleveland, OH, USA). The registration was based on the translation in three directions (left--right (LR), anterior--posterior (AP), and superior--inferior (SI), each defined as + and -- values) because CT images cannot be rotated for dose calculation with the XiO-N system. Prostate contours were generated on all TRCT images by the rigid image registration method based on the PlanCT, and the rectum and bladder were manually delineated on all TRCT images. After generation and delineation, an oncologist and medical physicist checked the contours. Additionally, deviations from the volumes on the PlanCT to those measured on each TRCT were calculated. The WELs in the AP direction were then measured from the patient\'s body surface to the isocenter of the beam\'s direction plane, and the correlation between the prostate displacements and the WEL deviations in the AP direction was evaluated.

Initial and boost fields on horizontal and vertical (LR and AP directions, respectively) were generated and used for evaluation. Examples of the dose distributions associated with vertical and horizontal fields are shown in [Figure 1](#F1){ref-type="fig"}. The daily dose distributions for the initial and boost fields in the vertical and horizontal directions were recalculated on all TRCT sets at the bone-matching position. The dose--volume parameters of the prostate V95, rectum V95, V50, and V10 were also evaluated. For the rectal volume evaluation, the rectal wall was considered to be 3 mm thick, as described previously ([@B24], [@B25]). Additionally, the correlation between the prostate displacement and the dose--volume parameters of the prostate V95 and those between the rectal volume deviation and the deviations in the dose--volume parameters of the rectum V95, V50, and V10 were evaluated.

![Examples of dose distributions for **(A,B)** initial fields and **(C,D)** boost fields from **(A,C)** the horizontal direction and **(B,D)** the vertical direction. The green, almond, cyan, blue, and magenta lines delineate the prostate, PTV1, PTV2, bladder, and rectum, respectively.](fonc-10-01264-g0001){#F1}

To estimate the appropriate margins in CIRT for prostate cancer to ensure robustness against inter-fractional anatomical changes, vertical and horizontal fields were generated on the PlanCT with 0-, 2-, 4-, and 6-mm isotropic margins to the prostate. The dose distributions were then recalculated for all TRCT images at the bone-matching position. Sigmoid functions were fitted to the plot of the acceptance ratio vs. the isotropic margin size to identify the margin that enables 95% of the examined patients to achieve an acceptable condition (prostate V95 \> 98%) for each field in the vertical and horizontal directions.

Statistics
----------

All dose--volume parameters for vertical and horizontal fields, as well as the prostate displacements and WEL deviations in the AP direction, were compared using *t*-tests; *p* = 0.05 was considered statistically significant.

Results {#s3}
=======

The measured prostate displacements and rectal and bladder volume variations are shown in [Figure 2](#F2){ref-type="fig"}. The mean ± standard deviation of the prostate displacement for all patients were 0.08 ± 0.50, 0.46 ± 1.32, and −0.12 ± 1.87 mm in the LR, SI, and AP directions, respectively, and those for the rectal and bladder volume deviations were −1.07 ± 9.37 and 2.55 ± 95.36 ml, respectively. The correlation between prostate displacement and WEL deviation in the AP direction is shown in [Figure 3](#F3){ref-type="fig"}. The mean ± standard deviation of the prostate displacement and WEL deviation were −0.13 ± 1.88 and 0.82 ± 2.04 mm, respectively; the mean difference was not statistically significant.

![Box plots of prostate displacements and inter-fractional variations in the rectal and bladder volumes for each patient.](fonc-10-01264-g0002){#F2}

![Correlation between prostate displacement and water-equivalent path length (WEL) deviation in the AP direction. The dotted line shows linear fitting to the data.](fonc-10-01264-g0003){#F3}

The dose--volume parameters on PlanCT and TRCT are shown in [Table 2](#T2){ref-type="table"}. There were no statistically significant differences between the daily prostate V95 with initial fields in the vertical and horizontal directions. For the boost field, however, the prostate V95 was significantly lower in the vertical than horizontal direction.

###### 

Dose volume of prostate and rectum.

                                    **Initial**    **Boost**                                               
  ----------- ---------- ---------- -------------- --------------- --------- -------------- -------------- ---------
  Plan        Prostate   V95 (%)    100 ± 0        100 ± 0         --        99.89 ± 0.07   99.99 ± 0.02   0.002
              Rectum     V95 (ml)   2.03 ± 0.48    1.93 ± 0.38     0.097     0.01 ± 0.02    0.03 ± 0.04    0.188
                         V50 (ml)   3.10 ± 0.64    3.64 ± 0.70     \<0.001   1.06 ± 0.23    1.90 ± 0.40    \<0.001
                         V10 (ml)   9.42 ± 1.79    5.11 ± 0.90     \<0.001   6.08 ± 0.94    3.26 ± 0.67    \<0.001
  Daily       Prostate   V95 (%)    99.89 ± 0.62   100.00 ± 0.00   0.067     95.95 ± 5.81   97.88 ± 3.87   \<0.001
              Rectum     V95 (ml)   1.93 ± 1.25    1.88 ± 0.96     0.432     0.37 ± 0.69    0.43 ± 0.65    0.145
                         V50 (ml)   3.09 ± 1.63    3.57 ± 1.14     \<0.001   1.19 ± 1.28    1.83 ± 0.98    \<0.001
                         V10 (ml)   9.43 ± 2.16    5.04 ± 1.37     \<0.001   6.06 ± 1.99    3.22 ± 1.11    \<0.001
  Deviation   Prostate   V95 (%)    −0.11 ± 0.62   0.00 ± 0.00     0.067     −4.06 ± 5.83   −2.12 ± 3.88   \<0.001
              Rectum     V95 (ml)   −0.10 ± 1.22   −0.05 ± 1.00    0.349     0.36 ± 0.69    0.40 ± 0.66    0.317
                         V50 (ml)   −0.01 ± 1.60   −0.07 ± 1.14    0.402     0.14 ± 1.30    −0.07 ± 1.00   0.005
                         V10 (ml)   0.03 ± 1.80    −0.07 ± 1.34    0.258     −0.01 ± 1.67   −0.03 ± 1.17   0.881

*The Plan values show the mean ± standard deviation for each of 10 patients, the Daily values show the mean ± standard deviation of the 118 images from irradiation days, and the Deviation values show the mean ± standard deviations of the differences between the Plan and Daily values. Initial shows the fields to the PTV1, and Boost shows the field to the PTV2. Vx, volume receiving greater than x% of the prescription dose*.

The correlations between prostate displacement and prostate V95 and between rectal volume deviation and rectal dose volume are shown in [Figure 4](#F4){ref-type="fig"}. The correlations of prostate displacement with bladder volume deviation and rectal volume deviation in the AP direction are shown in [Figure 5](#F5){ref-type="fig"}. The prostate and rectal dose volume and acceptance ratio graphs are shown in [Figure 6](#F6){ref-type="fig"}. Based on these data, adequate margins in the vertical field and horizontal field for an acceptance ratio of 95% were determined to be 2.2 and 3.0 mm, respectively.

![Correlation between **(A--C)** prostate displacement and prostate dose volume deviation (sigmoid fitting) and between **(D--F)** rectal volume deviation and rectal dose volume deviation (linear fitting). The orange circles and lines show the parameters of vertical fields, and the light blue circles and lines show the parameters of horizontal fields. The filled circles and solid lines show initial fields, and the hollow circles and dotted lines show boost fields.](fonc-10-01264-g0004){#F4}

![Correlation between deviations in **(A)** rectal volume and **(B)** bladder volume vs. the prostate displacement in the AP direction.](fonc-10-01264-g0005){#F5}

![Graphs of prostate and rectum dose--volume parameters and acceptance ratio in each margin. **(A)** Prostate V95. **(B)** Acceptance ratio when prostate V95 \> 98% with fitted sigmoid functions. Rectal **(C)** V95, **(D)** V50, and **(E)** V10 values as functions of the margin used. Orange circles show vertical fields, and light blue circles show horizontal fields. \*Statistically significant difference.](fonc-10-01264-g0006){#F6}

Discussion {#s4}
==========

Our results showed that the average inter-fractional prostate displacement was 0.46 ± 1.32 mm in the SI direction and −0.12 ± 1.87 mm in the AP direction. Our measured displacements were similar to those measured from in-room CT ([@B26]) using a flat-type shell similar to that used in this study. However, these displacements were smaller than those measured under cone-beam CT ([@B27], [@B28]) or megavoltage CT ([@B29]) with different shell types or without the shell. It was hypothesized that the patient immobilization induced by pressing with a flat shell may also suppress prostate displacement.

[Table 2](#T2){ref-type="table"} shows that the prostate coverage was better with the horizontal field than with the vertical field. The difference was statistically significant for the boost fields because they do not have a margin in the posterior direction from the prostate, which results in less consistent coverage than with the initial fields, which have a large margin. There are two possible reasons for the target coverage with the vertical field being worse than that with the horizontal field. The first is that the coverage of the vertical field in the treatment planning is slightly worse than that of the horizontal field. Because the dose calculation in XiO-N is a forward calculation, the 95% isodose line does not perfectly match the PTV. This effect is mostly observed along the beam axis rather than in the lateral direction perpendicular to the beam and results in worse coverage on the posterior side of the prostate with the vertical field than with the horizontal field. The second possible explanation is that the prostate displacements in the AP direction are slightly larger than the WEL changes in the AP direction, as illustrated in [Figure 3](#F3){ref-type="fig"}, although the difference was not statistically significant. The prostate displacements in the AP direction affect the dose distribution in the vertical field, while the WEL deviations in the AP direction influence the dose distribution in the horizontal field. Thus, it is possible that the vertical field is more strongly affected by inter-fractional WEL deviations than is the horizontal field by the prostate displacements, which results in worse target coverage with the vertical field. Hence, if target coverage is a priority, the use of a vertical boost field may not be ideal.

There was no significant difference in the rectal wall dose between the rectum V95 values associated with the initial and boost fields. However, the vertical fields resulted in significantly lower rectum V50 values and significantly higher V10 values than the horizontal fields. It was assumed that the distal fall off in the vertical field was steeper than the lateral penumbra in the horizontal field, which explains why a significant difference was observed in the rectum V50 but not in the V95. Additionally, the difference in the rectum V10 values was attributed to the fact that the dose on the distal tail in the vertical field was higher than that on the lateral tail in the horizontal field. While these results capture inter-fractional anatomical changes, similar tendencies were observed in our previous study considering setup uncertainties and beam range uncertainties ([@B15]). Therefore, it can be concluded that a vertical field is more effective for reducing the rectal middle dose, while a horizontal field is more effective for reducing the rectal low dose.

[Figure 4](#F4){ref-type="fig"} shows that the correlation coefficients between the inter-fractional prostate displacement and prostate coverage were high in the SI and AP directions but low in the LR direction. Furthermore, the correlations of the prostate displacement with the deviations in the bladder volume and rectal volume were low (*R* = 0.25 and 0.34), as shown in [Figure 5](#F5){ref-type="fig"}. This finding indicates that it is difficult to control the prostate displacement only by managing the inter-fractional bladder volume, rectal gas, and presence of feces in the rectum. However, monitoring the bladder volume and rectal gas and feces may effectively prevent changes in the bladder and rectal volumes as shown in this study because the TRCT images were acquired after these steps were taken; hence, such management techniques may be necessary to ensure patient safety. Because vertical fields are more sensitive to prostate displacements (because the fitting curve is steeper than in the horizontal field), and because the correlation coefficients between the rectal volume deviation and rectal wall dose volume ranged from medium to high, it can be inferred that managing the rectal gas or feces is important to control the rectal dose. In particular, because the ratio of the increase in the rectal dose to the increase in the rectal volume is higher with a vertical than horizontal field, more care must be taken when using a vertical field.

[Figure 6](#F6){ref-type="fig"} shows that vertical fields need smaller margins than horizontal fields. When generating the treatment planning beam, we use a spread-out Bragg peak size of 5 mm for a horizontal field and 10 mm for a vertical field in our facility. Therefore, an extra dose is delivered upstream of the target to ensure the target dose in each directional field. Because the inter-fractional prostate displacements tend to be larger in the AP than LR direction, as shown in [Figure 2](#F2){ref-type="fig"}, it is assumed that vertical field, that extra dose is delivered in anterior direction, provide greater target coverage than the horizontal field when the margin is small. In practice, horizontal fields provide greater target coverage when the margin is sufficient (4 mm). Therefore, the challenge in delivering an extra dose is a situation specific to our facility; however, the same problem would occur at other facilities that use passive irradiation. Thus, 3-mm margins would be required for both vertical and horizontal fields.

The scope of this study is limited to the effects of inter-fractional changes because the TRCT images were acquired only one time after each irradiation. However, there may be more intra-fractional changes during the treatment. Although previous studies have indicated that the intra-fractional changes are smaller than the inter-fractional changes ([@B28]--[@B30]), it is necessary to consider both changes when determining the appropriate margins. Assuming that the intra-fractional change is equivalent to the inter-fractional change, a margin of 3 × √2 = 4.2 mm would be required to ensure patient safety.

Furthermore, this study focused on single beams. If using a combination of vertical and horizontal fields, the lower rectal dose would increase more than when using only a horizontal field; however, the dose distributions can be expected to be more robust because the uncertainty of each field is distributed. Additionally, this study considered only the daily dose distribution. Because accumulating dose distributions are effective for predicting treatment outcomes and toxicities ([@B31]), we plan to evaluate the cumulative dose distributions in a future study. However, care should be taken because the use of a deformable image registration method to calculate the accumulated dose may produce some errors ([@B32]).

Another limitation of this study was that although 118 TRCT images were acquired, the number of patients in the sample set was low (10 patients). Therefore, further analyses with more patient data are necessary. Additionally, our evaluation did not include the seminal vesicle volume. Because the dose coverage would decrease because of inter-fractional movements of the seminal vesicles, further evaluations are needed. Moreover, the prostate contours observed on TRCT were generated by the rigid image registration method from the PlanCT, which may include small errors because of inter-fractional anatomical changes.

Conclusion {#s5}
==========

In this study, we evaluated the robustness of horizontal and vertical fields against inter-fractional anatomical changes using daily CT images acquired in the treatment room during CIRT for prostate cancer. The results showed that horizontal fields better ensure that the target dose is delivered than vertical fields. Vertical fields are effective for reducing the rectal middle dose, and horizontal fields are effective for reducing the rectal low dose. Finally, a 3-mm margin was found to be sufficient to ensure robustness against inter-fractional changes.
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